Tavotek Biotherapeutics advances medicines for patients with cancer, autoimmune conditions, and inflammatory diseases using antibody and peptide-based modalities. Its core research platforms are TavoSelect (a phage display library for conformational-selective full-length and single-domain antibodies), TavoPrecise (an engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform that targets previously undruggable targets). The company has product candidates at various stages of development and operates R&D centers in Lower Gwynedd, Pennsylvania and Suzhou, China. In November 2021 Tavotek closed a $35M Series B led by CS Capital with participation from Fontus Capital. The company intends to use the proceeds to accelerate Phase 1 clinical development of several antibody drugs beginning in early 2022, to advance CMC and IND development of multiple oncology programs, and to further develop its multicyclic intracellular peptide (MIP) programs. These funds are intended to push multiple preclinical and early-clinical programs toward IND-enabling and clinical milestones. Tavotek Biotherapeutics focuses on developing biotherapeutic treatments for patients with unmet medical needs. The company was founded in early 2019. It maintains two R&D centers in Lower Gwynedd, Pennsylvania and Suzhou, China. Tavotek emphasizes innovation to improve patient well‑being. Over the past two months it completed Series A1 and A2 financings totaling over $20M. Earlier funding included an initial Round A investment from Apricot Capital.

Total raised

$55M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2021